Efficacy and Safety of Second‑generation FLT3 Inhibitors in Acute Myeloid Leukemia: A Systematic Review and Meta‑analysis of Randomized Controlled Trials

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2024 Oct 31

PMID 39478693

Authors

Wei-Ting Lin

Chien-Ming Chao

Cheng-Yao Lin

Ya-Ting Hsu

Sheng-Yen Hsiao

Teng-Song Weng

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is one of the most frequent forms of acute leukemia and the second most common leukemia subtype in adults. In 2020, the incidence of AML in the United States was estimated to be ~4 cases per 100,000 adults. The FMS-like tyrosine kinase 3 () internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutation are major prognostic indicators of AML. They are more frequently observed in younger AML patients (aged <60 years), likely due to their association with . Additionally, these mutations have a stronger negative impact on survival in younger patients. Therefore, quizartinib and gilteritinib are second-generation FLT3 inhibitors that are frequently applied for treating patients with AML. However, to the best of our knowledge, few studies have compared the efficacy of second-generation FLT3 inhibitors for AML treatment. Therefore, the present study conducted a comprehensive search for studies on the efficacy and safety of FLT3 inhibitors across PubMed, Embase, the Cochrane Library and ClinicalTrials.gov. The search criteria were limited to randomized controlled trials (RCTs). Subsequently, a meta-analysis was performed on a total of five randomized controlled trials, involving 1,543 participants in total, using a random-effects model. In each RCT, compared to the salvage chemotherapy used in the control group, the groups that received second-generation FLT3 inhibitors experienced significant improvements in overall survival (hazard ratio, 0.717; 95% CI, 0.604-0.850; P<0.001). In addition, overall survival was found to be consistent across the different types of second-generation FLT3 inhibitors used and different types of AML. The risks associated with a prolonged heart-rate corrected QT interval (QTc) interval were next evaluated. Compared with the salvage chemotherapy used in the control group, the second-generation FLT3 inhibitor group exhibited a significantly higher risk of having a prolonged QTc interval (odds ratio, 6.311; 95% CI, 3.061-13.013; P<0.001). In conclusion, these findings suggest that second-generation FLT3 inhibitors can improve the overall survival of patients with AML. However, QTc prolongation is a potential adverse effect that should be monitored.

References

Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

Jaramillo S, Le Cornet L, Kratzmann M, Krisam J, Gorner M, Hanel M . Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. Trials. 2023; 24(1):591. PMC: 10504729. DOI: 10.1186/s13063-023-07421-x. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Mohebbi A, Shahriyary F, Farrokhi V, Bandar B, Saki N . A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia. Leuk Res. 2024; 141:107505. DOI: 10.1016/j.leukres.2024.107505. View

Lee L, Hernandez D, Rajkhowa T, Smith S, Raman J, Nguyen B . Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2016; 129(2):257-260. PMC: 5234222. DOI: 10.1182/blood-2016-10-745133. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T . Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol. 2021; 26(11):2131-2141. PMC: 8522999. DOI: 10.1007/s10147-021-02006-7. View

Baracaldo-Santamaria D, Llinas-Caballero K, Corso-Ramirez J, Restrepo C, Dominguez-Dominguez C, Fonseca-Mendoza D . Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation. Int J Mol Sci. 2021; 22(15). PMC: 8347245. DOI: 10.3390/ijms22158090. View

10.

Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R . Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017; 35(5):556-565. PMC: 5613053. DOI: 10.1007/s10637-017-0470-z. View

11.

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

12.

Suknuntha K, Choi Y, Jung H, Majumder A, Shah S, Slukvin I . Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition. Front Oncol. 2020; 10:585151. PMC: 7756118. DOI: 10.3389/fonc.2020.585151. View

13.

Larrosa-Garcia M, Baer M . FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Mol Cancer Ther. 2017; 16(6):991-1001. PMC: 5600895. DOI: 10.1158/1535-7163.MCT-16-0876. View

14.

Wander S, Levis M, Fathi A . The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014; 5(3):65-77. PMC: 4031904. DOI: 10.1177/2040620714532123. View

15.

Slominski R, Raman C, Chen J, Slominski A . How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 2023; 46(4):263-275. PMC: 10038913. DOI: 10.1016/j.tins.2023.01.003. View

16.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Dohner H, Dohner K, Schittenhelm M . Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013; 12:19. PMC: 3637582. DOI: 10.1186/1476-4598-12-19. View

17.

Ruglioni M, Crucitta S, Luculli G, Tancredi G, Del Giudice M, Mechelli S . Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol. 2024; 201:104424. DOI: 10.1016/j.critrevonc.2024.104424. View

18.

Erba H, Montesinos P, Kim H, Patkowska E, Vrhovac R, Zak P . Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388):1571-1583. DOI: 10.1016/S0140-6736(23)00464-6. View

19.

Wang E, Montesinos P, Minden M, Lee J, Heuser M, Naoe T . Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022; 140(17):1845-1857. PMC: 10653009. DOI: 10.1182/blood.2021014586. View

20.

Kottaridis P, Gale R, Frew M, Harrison G, Langabeer S, BELTON A . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the.... Blood. 2001; 98(6):1752-9. DOI: 10.1182/blood.v98.6.1752. View